ClinicalTrials.gg

Rhinosinusitis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 251 studies for Rhinosinusitis across more than 10 countries. 69 are recruiting or about to start. 146 of them are mainly about Rhinosinusitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Status

Completed
123
Recruiting
33
Not yet recruiting
33
Status unknown
24
Active, not recruiting
13
Withdrawn
12

Phase

Phase 2
43
Phase 3
41
Phase 4
35
Phase 1
17
Early Phase 1
5

Where

United States
71
China
40
Canada
31
Germany
21
Egypt
15
France
14

Who develops what

Add Rhinosinusitis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 15 programs from 14 companies, 5 with this as their studies’ main aim; 9 with a live phase 3 study; 6 primary completions in the next 12 months. Compare Sanofi, Akeso and AstraZeneca here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Mometasone FuroateRecent, repeated
Evidence
  • NCT07903194 · Shanghai Mabgeek Biotech.Co.Ltd · Phase 3 · live · background · “Mometasone Furoate Nasal Spray” · registered Oct 2026
  • NCT06914908 · Sanofi · Phase 2 · live · background · “Mometasone furoate nasal spray (MFNS)” · registered Apr 2025
  • NCT06834360 · Sanofi · Phase 3 · live · background · “Mometasone furoate nasal spray (MFNS)” · registered Feb 2025
  • NCT06834347 · Sanofi · Phase 3 · live · background · “Mometasone furoate nasal spray (MFNS)” · registered Feb 2025
  • NCT06691113 · Sanofi · Phase 2 · background · “Mometasone furoate nasal spray (MFNS)” · registered Nov 2024
Organon & Co.62% of its industry studiesUS: off-patent, 12 generics marketed36 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
tezepelumabApproved: US 2021 · EU 2022☆ Track2 live phase-3 studies: NCT07520162, NCT06706817AstraZeneca
CM512☆ Track1 live phase-3 study: NCT07807826Keymed Biosciences Co.Ltd
MMH-407☆ Track1 live phase-3 study: NCT06901297Materia Medica Holding
FluticasoneApproved: US☆ Track1 live phase-3 study: NCT06850805optinose us inc

The 4 in phase 3 with the nearest primary completion, of 15 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (6)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 13 Jan 2027 est.tezepelumab · AstraZeneca · Phase 3 main aimNCT06706817 A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab — primary endpoint: Change from baseline in nasal congestion · 181 enrolled
  • 17 Feb 2027 est.itepekimab · Sanofi · Phase 3 named, not the main aimNCT07424144 An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps — primary endpoint: Incidence of treatment-emergent adverse events (AEs), adverse events of special interest (AESIs), serious adverse events (SAEs), AEs leading to death, and AEs leading to permanent treatment discontinuation · 59 enrolled
  • 28 Feb 2027 est.Lisinopril · Longbio Pharma · Phase 2 named, not the main aimNCT07313917 A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) — primary endpoint: Change from baseline in Nasal Polyps Score (NPS) at Week 24 · 150 enrolled

3 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Rhinosinusitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Corticosteroids 1 open

Coming up

30studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 33 Rhinosinusitis studies recruiting now, 14 (42%) set no upper age limit and 13 (39%) stop at 75 or younger. 4 (12%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 6 (18%) take healthy volunteers.

Recruiting studies that take each age, of 33
AgeWomenMen
100 (0%)0 (0%)
1830 (91%)30 (91%)
3032 (97%)32 (97%)
4032 (97%)32 (97%)
5032 (97%)32 (97%)
6529 (88%)29 (88%)
7524 (73%)24 (73%)
8518 (55%)18 (55%)

Across all 251 studies, recruiting or not: 43% stop at 75 or younger and 20% at 65; 16% take children; 0% are for women only and <1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Rhinosinusitis studies take

Of 24 phase 3 interventional studies under Rhinosinusitis, half reached primary completion within 22 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 218 mo13–26 · 16 studies——
Phase 322 mo19–37 · 24 studies——
Phase 433 mo14–35 · 14 studies——
Interventional, no phase16 mo6–36 · 33 studies——
Observational27 mo15–71 · 22 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 251. Browse all 251 → or search them.